und Thoraxchirurgie Leiter - Landeskrankenhaus Feldkirch

3. Wissenschaftliche Tätigkeiten, Publikationen, Fortbildung und
Unterrichtstätigkeit
I. Wissenschaftliche Publikationen und Vorträge
9
1) Knauer M, Konstantiniuk P, Haid A, Wenzl E, Köberle-Wührer R, Riegler-Keil M,
Pöstlberger S, Reitsamer R, Schrenk P:
Multicentric Breast Cancer: Sentinel Node Biopsy as a Diagnostic Tool
Methods of Cancer Diagnosis, Therapy and Prognosis; Vol 1, 99-108
2) Knauer M, Haid A, Schneider Y, Köberle-Wührer R, Lang A, Winder T, Alton R,
Jasarevic Z, Säly C, Offner FA, Wenzl E, de Vries A:
Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve
outcome in early-stage breast cancer.
Eur J Surg Oncol. 2008 Nov 13: [Epub ahead of print]
3) Knauer M, de Vries A, Wenzl E, Haid A:
Standardization of pathologic complete response rates in breast cancer
treatment.
Breast Cancer Res Treat. 2008 Jul;110(2):395-6. Epub 2007 Sep 13.
4) Knauer M, Bartsch R:
Risikofaktoren für Entwicklung von Hirnmetastasen bei Brustkrebs.
Jatros Hämatologie & Onkologie. 2008;4:64-65
5) Knauer M, Haid A, de Vries A, Schneider Y, Lang A, Winder T, Alton R, Wenzl E:
Does combination of neoadjuvant and adjuvant chemotherapy improve outcome
in operable breast cancer patients?
Eur Surg 2008: Suppl, Abstract P006
6) Knauer M, Rottenfusser A, Bartsch R, Dieckmann K, Wenzel C., Fromm S, Eiter
H, Steger GG, Zielinski CC, de Vries A:
Analysis of risk factors predicting time to development of brain metastases
J Clin Oncol 26: 2008 (May 20 suppl; abstr 1076)
7) Knauer M, Retèl V, Bueno-de-Mesquita JM, Rutgers EJT, van Harten WH,
Rodenhuis S, van de Vijver MJ, van 't Veer LJ, Linn SC:
Benefit of the 70-gene profile for widely used guidelines: an answer to increased
selection for adjuvant chemotherapy in breast cancer.
Breast Cancer Res Tr 2008 (Suppl), Abstract 1084
8) Knauer M, Cardoso F, Mook S, Bedard P, Koornstra R, Kok M, Bueno-de-
Mesquita JM, Wesseling J, van de Vijver MJ, Linn SC, Rutgers EJT, van 't Veer
LJ:
Identification of a low risk subgroup in Her2-positive breast cancer by the 70gene
prognosis signature.
Breast Cancer Res Tr 2008 (Suppl), Abstract 4171
9) Esserman LJ, van't Veer LJ, Perou C, Rutgers EJT, Knauer M, Davis SE, I-SPY
Investigators, on Behalf of the I-SPY TRIAL Network: